Demographics | |||
Mean age | 58.4±8.12 years | ||
Gender | 84 males (82.4%) | 18 females (17.6%) | |
Mean body mass index | 28.17±1.75 | ||
Smoking history | Ex-smokers 40 patients (39.2%) | Current smokers 27 patients (26.5%) | Non-smokers 35 patients (34.3%) |
History of alcohol or substance abuse | No patients | ||
Tumour characteristics | |||
Unilobar | 81 patients (79.4%) Grp 1: 44 pts (91.7%) Grp 2: 37 pts (68.5%) | Right lobe: 72 pts (70.6%) | Left lobe: 9 pts (8.8%) |
Bilobar | 21 patients (20.6%) Grp 1: 4 pts (8.3%) Grp 2: 17 pts (31.5%) | ||
Single nodule | 56 patients (54.9%) Grp 1: 31 pts (64.6%) Grp 2: 25 pts (46.3%) | ||
Multiple nodules | 46 patients (45.1%) Grp 1: 17 pts (35.4%) Grp 2: 29 pts (53.7%) | ||
Size: single nodule largest diameter or sum of largest diameter for 2–3 nodules | <5 cm: 18 patients (20%) | 5–8 cm: 47 patients (52.2%) | >8 cm: 25 patients (27.8%) |
BCLC staging | Total patients | Group 1 (n=48) | Group 2 (n=54) |
Stage A | 24 patients (23.5%) | 18 patients (37.5%) | 6 patients (11.1%) |
Stage B | 69 patients (67.6%) | 28 patients (58.3%) | 41 patients (75.9%) |
Stage C | 9 patients (8.8%) | 2 patients (4.2%) | 7 patients (13%) |
Group 1 consists of patients with no points added to the Child-Pugh score 1 month after TACE. Group 2 consists of patients with one or more points added to the Child-Pugh score 1 month after TACE.
BCLC, Barcelona Clinic Liver Cancer; Grp 1, group 1; Grp 2, group 2; TACE, transarterial chemoembolisation.